Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Paul Leslie Stockdale F.C.A., M.A. | CFO & Executive Director | 205k | -- | 1975 |
| Dr. Alexandre Akoulitchev M.A., Ma (Oxon), Ph.D. | Chief Scientific Officer & Executive Director | 237k | -- | 1962 |
| Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D | Executive Chairman | -- | -- | 1954 |
| Mr. Thomas G. Guiel B.A. | Chief Operating Officer | -- | -- | -- |
| David Blum | Senior Vice President of Marketing | -- | -- | -- |
| Dr. Ewan Hunter B.Sc., Ph.D., Ph.D., (KCL) | Chief Data Officer | -- | -- | -- |
| T. Demain | Company Secretary | -- | -- | -- |
Oxford BioDynamics Plc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 51
Description
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom. The company provides EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation, and monitoring of 3D genomic biomarkers to diagnose patients. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling. The company was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
Corporate Governance
Upcoming Events
June 16, 2025 at 7:30 AM UTC - June 20, 2025 at 7:30 AM UTC
Oxford BioDynamics Plc Earnings Date
Recent Events
Recent Events Information Not Available